Polygenic scores (PGS) have been leveraged to detect gene-environment interactions across many complex traits and environmental variables. While PGSxE regression is potentially more powerful than single-variant genome-wide interaction studies (GWIS) due to the aggregation of genetic effects and reduced multiple testing burden, standard PGS reflect many different biological mechanisms, limiting interpretation and potentially diluting pathway-specific interaction signals. Previous work has uncovered significant genome-wide PGSxBMI signal for liver function, but there is an opportunity for additional and more interpretable discoveries. Here, we leverage pathway-specific polygenic scores (pPGS) to discover novel mechanism-specific gene-adiposity interactions. We tested for adiposity interactions impacting three liver-related biomarkers (ALT, AST and GGT) using (1) a standard, genome-wide PGS, (2) an array of pPGS containing variant subsets derived from KEGG pathways, and (3) a GWIS. For ALT, we identified 49 significant pPGSxBMI interactions at a Bonferroni corrected p < 2.7x10-4, 80% of which were not explained by genes close to the 8 loci found in the associated GWIS. Across all biomarkers, we found interactions of BMI with 83 unique pPGS-based on KEGG pathways. We tested alternate pathway collections, including Hallmark gene sets and the KEGG Medicus database, finding that the choice of pathway collection strongly impacts discovery. Our results support the use of pPGS for well powered and interpretable discovery of pPGSxE interactions with adiposity-related exposures for liver biomarkers and motivate future studies using a broader collection of exposures and outcomes.

The authors have declared no competing interest.

KEW was supported by K01DK133637.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This research was conducted using the UK Biobank resource under application no. 277892 and Not Human Subjects Research determination NHSR-4298 at the Broad Institute of MIT and Harvard.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

No new genetic or phenotypic data have been generated for this study. The UK Biobank data, including genetic and phenotypic data, are under controlled access but can be obtained through application at https://www.ukbiobank.ac.uk/. UK Biobank will consider data applications from bona fide researchers for health-related research that is in the public interest.